ALFA Filings
Every announcement, straight from the exchange
Every Cipla business update announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements with these filters
Cipla's subsidiary InvaGen received zero Form 483 observations in a routine USFDA cGMP inspection. The clean outcome confirms compliance at its US manufacturing facility.
Cipla reported receiving seven inspectional observations from the USFDA following a cGMP inspection at its Pithampur facility. The company intends to address these observations promptly.
Cipla announced that its subsidiary, InvaGen, received the Establishment Inspection Report from the USFDA, officially closing the inspection of its Hauppauge facility.
Cipla informed that a USFDA inspection at its InvaGen subsidiary in New York concluded with one Form 483 observation, which will be addressed promptly.
Cipla disclosed that ESG Rating Provider ESGRisks.ai revised its ESG score from 68 to 64. The update is filed under Regulation 30.
USFDA classified Cipla's Verna, Goa facility inspection as Voluntary Action Indicated (VAI). This status allows continued operations while the company addresses administrative observations.